GlaxoSmithKline Secrets & Lies Part 2

Stuart Dollow, medical director of GlaxoSmithKline UK, "We published the results of all its studies on all drugs "whether negative or positive".

Stuart Dollow, medical director of GlaxoSmithKline UK

Product liability cases against drug companies like GlaxoSmithKline are often settled with an agreement that the potentially incriminating data found in the drug company files will be sealed or kept secret. In the case of Lacuzong v. GlaxoSmithKline, my report disclosed extensive manipulation of data concerning Paxil's adverse effects, including rates of suicidality, psychomotor agitation (akathisia), and over-stimulation. In a subsequent lawsuit against the company, my report was unsealed and is now available to the public. I placed the entire report on my website and published three scientific articles based on it.

Peter R. Breggin, MD

----------------------------------------------------------------


Panorama: Did GlaxoSmithKline act promptly in getting this information to you?

Prof Sir ALASDAIR BRECKENRIDGE Chair, Medicines Health and products Regulatory Agency

This is a matter which we are investigating at the present time. There is an investigation going on, being conducted by the.. one of this.. the inspection and enforcement sector of the agency and with lawyers to decide whether or not they did.

I enquired about this to the MHRA under the Freedom of Information Act. It has been over two years since this initial statement from Prof Sir Alasdair Breckenridge.

Here is the reply I recieved:

Thank you for your enquiry of 4th December 2006. I am writing to let you know that we are unable to supply the information you have requested. Under the Freedom of Information Act (FOIA) certain exemptions apply to the information we can make available. The information you have requested concerns a criminal investigation and is subject to the exemption contained in the FOIA, namely exemption 30. We have concluded that disclosing this information would not be appropriate because it would prejudice an ongoing criminal investigation. I am satisfied that both categories in exemption 30 are applicable;

a) where information has at any time been held for the purpose of specified criminal and other investigations or proceedings; and

b) where information relates to the obtaining of information from confidential sources and was obtained or recorded for a number of specified investigations or proceedings

Therefore it would not be in the public interest to disclose the outcome of the criminal investigation in advance of any potential court proceedings

---------------------------------------------------------------


...if you imagine a school of more than a thousand children all of whom are deeply troubled by depression, less than a small class size would have these suicidal thoughts or attempts, so it's a small but important signal…

Dr ALASTAIR BENBOW Head of European Psychiatry, GlaxoSmithKline

Thanks for that scenario Dr Benbow. You clearly show that you are a man full of compassion

---------------------------------------------------------------


There is very good clinical trial evidence that these drugs do not cause suicide, they do not cause suicidal thoughts in adults. There is a very large database.

Prof Sir ALASDAIR BRECKENRIDGE Chair, Medicines Healthcare and products Regulatory Agency

What Prof Sir ALASDAIR BRECKENRIDGE fails to tell you is the MHRA have NOT examined the raw data, basically they examine the data that GSK give them, in other words they examine the positive data and NOT the negative data

----------------------------------------------------------


More Coming Soon

Fiddy